Efficacy and Safety of Intravenous Immunoglobulin in Patients with Metastatic Melanoma

Authors

  • JACOB SCHACHTER,

    1. Institute of Oncology, Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
    2. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
    Search for more papers by this author
    • *

      The first two authors contributed equally to the paper.

  • URIEL KATZ,

    1. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
    2. Center for Autoimmune Diseases, Department of Internal Medicine “B,” Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
    Search for more papers by this author
    • *

      The first two authors contributed equally to the paper.

  • ARIE MAHRER,

    1. Institute of Radiology, Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
    Search for more papers by this author
  • DOV BARAK,

    1. Institute of Oncology, Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
    Search for more papers by this author
  • LIAT ZIEGEL BEN DAVID,

    1. GammaCan International, Inc., Kiryat Ono, Israel
    Search for more papers by this author
  • JACOB NUSBACHER,

    1. GammaCan International, Inc., Kiryat Ono, Israel
    Search for more papers by this author
  • YEHUDA SHOENFELD

    1. Center for Autoimmune Diseases, Department of Internal Medicine “B,” Sheba Medical Center, Tel-HaShomer, Ramat Gan, Israel
    2. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel
    Search for more papers by this author

Address for correspondence: Y. Shoenfeld, M.D., F.R.C.P. (Hon.)., Department of Medicine B, Sheba Medical Center, Tel-HaShomer 52621, Israel. Voice: +972-3-5302652; fax: +972-3-5352855.
 Shoenfeld@post.tau.ac.il

Abstract

Abstract: We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.

Ancillary